A step-by-step acquisition strategy for aggregating Medicare-certified home health agencies across contiguous geographies — from target screening through CHOW completion to PE-backed exit.
Find Home Health Agency Acquisition TargetsThe U.S. home health industry is a $113 billion market projected to exceed $170 billion by 2030, driven by an aging Baby Boomer population, CMS's ongoing shift toward value-based care, and the cost advantages of home-based versus institutional care. The sector remains highly fragmented, with thousands of independent, owner-operated agencies generating $1M–$5M in annual revenue — many run by nurse or therapist founders nearing retirement with no succession plan in place. This fragmentation creates a compelling opportunity for disciplined acquirers to aggregate contiguous agencies, centralize back-office functions, optimize payor mix, and build a scalable regional platform that commands premium exit multiples from larger strategic buyers or private equity sponsors. Roll-up execution in home health requires deep understanding of CMS certification requirements, the change-of-ownership (CHOW) process, billing compliance risks, and the labor dynamics that make staff retention the central integration challenge. This guide provides a structured playbook for buyers pursuing a home health roll-up strategy in the lower middle market.
Home health agencies represent one of the most attractive roll-up targets in the lower middle market for several converging reasons. First, the industry is structurally fragmented — the majority of Medicare-certified agencies are small, independently owned operations where the founder serves as administrator, primary referral relationship manager, and clinical lead simultaneously. This owner-dependency creates both the motivation to sell and the integration risk to manage. Second, Medicare certification and state licensure create genuine barriers to entry that protect acquired revenue streams; a new competitor cannot simply open an agency and begin billing Medicare without 2–3 years of regulatory approvals. Third, the aging U.S. population guarantees sustained demand — the number of Americans over 65 is projected to reach 80 million by 2040 — making home health one of the few industries with a built-in secular growth tailwind independent of economic cycles. Fourth, CMS's Patient-Driven Groupings Model (PDGM) and Home Health Value-Based Purchasing (HHVBP) programs are squeezing margins for smaller operators who lack the clinical infrastructure to optimize episode management, creating motivated sellers and enabling well-capitalized buyers to acquire at distressed-adjacent multiples relative to the platform value they are building. Finally, PE-sponsored home health platforms have historically exited at 8–12x EBITDA, creating significant multiple expansion opportunity for acquirers who enter at 3.5–6x at the individual agency level.
The core roll-up thesis in home health is straightforward: acquire Medicare-certified agencies in contiguous geographies at 3.5–6x EBITDA, centralize billing, compliance, HR, and technology infrastructure across the portfolio, improve clinical outcomes scores to drive better PDGM reimbursement rates, diversify payor mix toward private pay and managed care to reduce government reimbursement dependency, and exit the combined platform to a regional operator or PE sponsor at 8–12x EBITDA. The margin expansion story is driven by three mechanisms. First, shared services consolidation eliminates redundant administrative costs — billing, payroll, credentialing, and compliance functions that each standalone agency runs independently can be centralized at a fraction of the per-agency cost. Second, clinical protocol standardization across the portfolio improves OASIS scoring accuracy and episode management, increasing Medicare reimbursement per episode under PDGM. Third, the combined entity's scale creates negotiating leverage with managed care plans to secure private-pay and Medicare Advantage contracts unavailable to a single sub-$2M agency. A well-executed roll-up targeting four to six agencies across a regional market can reach $8M–$20M in combined revenue with 15–22% EBITDA margins, a profile that attracts institutional buyers and commands the premium multiples that create transformative returns for the roll-up sponsor.
$1M–$5M annual revenue per agency
Revenue Range
$150K–$800K EBITDA per agency (10–20% margins)
EBITDA Range
Platform Agency Acquisition and Infrastructure Build
Identify and acquire the anchor agency — typically a $2M–$4M revenue Medicare-certified operation with a strong compliance record, capable non-owner management team, and established physician and hospital referral relationships. This first acquisition establishes the legal and operational infrastructure for the roll-up: centralized billing and EHR platform, compliance program, HR infrastructure, and the management team that will absorb subsequent acquisitions. Prioritize agencies with CMS star ratings of 3.5 or above and low hospitalization rates, as these clinical metrics will define the platform's reputation with referral sources and managed care plans from day one. Negotiate an asset purchase structure with a holdback of 10–15% tied to successful CHOW completion and payor re-enrollment, which typically takes 90–180 days from filing.
Key focus: CHOW process initiation, CMS certification continuity, EHR and billing system standardization, and management team retention agreements
Geographic Adjacency Screening and Pipeline Development
Build a proprietary deal pipeline targeting agencies in contiguous counties or ZIP codes that fill geographic gaps in the platform's Medicare service area. Use CMS's Provider of Services file and CASPER database to screen for agencies with active certifications, favorable OASIS outcome scores, and no open survey deficiencies. Engage healthcare business brokers and send direct outreach to agency owners identified through state licensure directories. Prioritize targets where the owner is over 60, has no identified successor, and operates in a market adjacent to the platform's existing referral network. A pipeline of 15–20 screened targets is needed to generate 3–5 actionable deals annually given the complexity of home health transactions and CHOW timelines.
Key focus: CMS database screening, direct seller outreach, referral network mapping, and building a 12–18 month acquisition pipeline of pre-qualified targets
Billing Compliance and Clinical Due Diligence
Home health due diligence must go beyond standard financial analysis to encompass a full billing compliance audit covering the last 3 years of Medicare and Medicaid claims. Engage a healthcare-specialized compliance attorney and billing auditor to review claim denial rates, overpayment risk, RAC audit history, and OASIS documentation accuracy. Verify that all skilled nursing and therapy staff hold current state licensure and that credentialing files are complete. Review all CMS survey history and confirm no open plans of correction or informal dispute resolution proceedings. Assess EVV compliance posture, as non-compliance creates both reimbursement risk and False Claims Act exposure that can follow the buyer through a stock purchase. Payor mix analysis should quantify revenue concentration by payer and referral source, with red flags triggered by any single source exceeding 40–50% of admissions.
Key focus: Third-party billing compliance audit, OASIS and star rating analysis, staff credentialing verification, EVV compliance review, and payor concentration risk quantification
Deal Structuring and CHOW Execution
Structure each add-on acquisition as an asset purchase with a holdback of 10–15% of purchase price tied to successful CHOW approval and active payor re-enrollment, protecting the buyer against the risk that Medicare billing authority is delayed or denied. Layer in an earnout of 12–24 months tied to patient census retention — targeting 80–90% of pre-close active patients — to align seller incentives with a smooth transition. File the CHOW application with CMS immediately upon signing, as the 90–180 day timeline is the critical path for every home health transaction. Work with a healthcare M&A attorney to structure the transition period agreement allowing the seller to continue billing under their Medicare provider number while the buyer's enrollment is pending, ensuring revenue continuity. For SBA-financed acquisitions, coordinate the 7(a) loan timeline with the CHOW filing to avoid closing delays.
Key focus: Asset purchase structure, CHOW filing timeline management, transition billing agreement, earnout design tied to census retention, and SBA 7(a) coordination
Post-Acquisition Integration and Shared Services Migration
Execute a 90-day integration playbook for each acquired agency: migrate billing to the platform's centralized billing system, onboard clinical staff to the standardized EHR platform, implement the platform's compliance and QAPI programs, and transition referral source relationships to the platform's regional sales team. Retain the acquired agency's administrator and director of nursing under 12–24 month employment agreements to preserve institutional knowledge and referral relationships during the transition. Centralize payroll, HR, credentialing, and compliance functions at the platform level to eliminate redundant administrative costs — the primary source of margin expansion in the early roll-up stages. Track OASIS outcome scores and star ratings quarterly to identify clinical improvement opportunities that will enhance PDGM reimbursement rates across the portfolio.
Key focus: 90-day integration playbook, billing and EHR migration, shared services centralization, clinical staff retention, and OASIS outcome monitoring
Payor Mix Optimization and Managed Care Contracting
As the platform reaches $5M–$10M in combined revenue and demonstrates consistent clinical outcomes, pursue Medicare Advantage and commercial managed care contracts that diversify revenue away from traditional fee-for-service Medicare. A platform operating 3–5 agencies across a regional market has the geographic coverage and patient volume that managed care plans require for network inclusion — a threshold few individual $2M agencies can meet. Target a payor mix of 60–70% traditional Medicare, 15–20% Medicare Advantage, 10–15% Medicaid, and 5–10% private pay as the platform matures. This diversification directly increases the platform's exit multiple by reducing perceived reimbursement concentration risk and demonstrating the clinical capability to perform under value-based contracts.
Key focus: Medicare Advantage contracting, managed care network enrollment, private pay program development, and payor mix reporting for exit positioning
Shared Services Centralization and Administrative Cost Reduction
Consolidating billing, payroll, HR, credentialing, and compliance functions across the portfolio eliminates the redundant administrative overhead each standalone agency carries. A single-agency operator typically spends 18–25% of revenue on administrative functions; a centralized platform can reduce this to 10–14% across four to six agencies, generating 400–800 basis points of EBITDA margin improvement without any change in clinical revenue. This is the fastest and most predictable source of value creation in the early stages of a home health roll-up.
OASIS Scoring Accuracy and PDGM Episode Optimization
Under the Patient-Driven Groupings Model, Medicare reimbursement per episode is determined by the accuracy and completeness of OASIS assessments conducted at admission. Many small, owner-operated agencies lack the clinical education infrastructure to optimize OASIS documentation, leaving reimbursement on the table. Implementing standardized OASIS training and clinical documentation audits across the portfolio — supported by a platform-level clinical quality director — typically increases per-episode reimbursement by 5–12% without any change in services delivered, directly expanding EBITDA margins.
Referral Source Network Consolidation and Geographic Density
Individual agencies build referral relationships with specific physicians, hospital discharge planners, and SNF social workers that are often personal rather than institutional. A roll-up platform operating across multiple contiguous counties can offer referral sources a single point of contact for a broader geographic service area, making the platform the preferred post-acute partner for regional hospital systems and physician groups. This geographic density strengthens referral relationships, increases admission volume, and creates a competitive moat that individual agencies cannot replicate.
Technology Infrastructure and EVV Compliance as a Competitive Differentiator
Many acquisition targets operate on legacy billing systems with limited EVV integration, creating compliance risk and operational inefficiency. Migrating acquired agencies to a modern EHR platform with integrated EVV, care plan management, and billing workflow automation reduces claim denial rates, accelerates cash collection, and eliminates the compliance exposure associated with manual visit verification. A platform-wide technology stack also enables centralized reporting on clinical outcomes, payor mix, and financial performance — essential for institutional buyers evaluating the platform at exit.
Labor Force Stabilization Through Scale and Benefits Enhancement
Skilled nurse and therapist retention is the single largest operational risk in home health. A roll-up platform can offer clinical staff career advancement pathways, professional development programs, and enhanced benefits packages — including health insurance, 401(k) matching, and sign-on bonuses — that individual $2M agencies cannot afford. Scale also enables the platform to build relationships with nursing schools and therapy programs for pipeline recruitment. Reducing skilled staff turnover from the industry average of 65–80% annually to 40–50% directly reduces per-visit labor costs and improves continuity of care metrics that drive star ratings and referral source loyalty.
Medicare Advantage and Value-Based Care Contracting
Traditional fee-for-service Medicare reimbursement is subject to annual rate adjustments and PDGM model changes that create revenue uncertainty. Diversifying toward Medicare Advantage and value-based care contracts — which often include shared savings arrangements tied to hospitalization reduction — increases revenue predictability and positions the platform as a value-based care partner rather than a commodity service provider. Platforms demonstrating strong HHVBP performance scores are increasingly positioned to capture shared savings payments that meaningfully exceed traditional FFS rates for high-acuity patients.
A home health roll-up platform targeting four to six agencies with $8M–$20M in combined revenue and 15–22% EBITDA margins is positioned to exit at 8–12x EBITDA to one of several buyer profiles. Regional and super-regional home health operators — including publicly traded companies such as LHC Group, Amedisys, or their successors — are active strategic acquirers of geographically dense, clinically high-performing platforms that extend their network coverage. PE-sponsored home health platforms executing their own roll-up strategies represent a second exit channel, as they acquire sub-platforms to accelerate geographic expansion without building market presence organically. A third pathway is a minority recapitalization with a healthcare-focused PE firm that provides growth capital while retaining the founding management team for a second bite of the apple at the larger platform's eventual exit. Exit preparation should begin 18–24 months before the target transaction date and include: commissioning a sell-side billing compliance audit to preempt buyer concerns, ensuring all CMS star ratings are current and improving, documenting managed care and Medicare Advantage contracts, and preparing a normalized EBITDA bridge that clearly illustrates shared services savings and clinical quality improvements achieved since the platform's first acquisition. A healthcare M&A advisor with specific home health transaction experience is essential to positioning the platform's PDGM performance data, payor mix trajectory, and CHOW-clean acquisition history in a buyer-ready information memorandum.
Find Home Health Agency Roll-Up Targets
Signal-scored acquisition targets matched to your roll-up criteria.
The CHOW process with CMS typically takes 90–180 days from the date of a complete application filing, though timelines can extend to 6–9 months in states with additional licensure transfer requirements or when CMS enrollment backlogs are high. During this period, the seller typically continues to bill Medicare under their existing provider number pursuant to a transition billing agreement negotiated at closing. For a roll-up platform, managing multiple simultaneous CHOW filings requires dedicated administrative resources and close coordination with a healthcare M&A attorney to avoid processing delays that disrupt revenue continuity at newly acquired agencies.
Individual Medicare-certified home health agencies in the $1M–$5M revenue range typically trade at 3.5–6x EBITDA, depending on CMS star ratings, payor mix quality, compliance history, and the strength of the management team independent of the owner. Agencies with strong clinical outcomes scores (4+ stars), diversified payor mix including managed care contracts, and a capable non-owner director of nursing and administrator command multiples at the higher end of the range. Agencies with owner-dependent referral relationships, compliance issues, or heavy reliance on a single hospital referral source will trade at 3.5–4x or require meaningful purchase price holdbacks. The multiple expansion opportunity — buying at 4–5x and selling the combined platform at 8–12x — is the fundamental economic engine of the home health roll-up thesis.
The three highest-risk integration failure points in home health roll-ups are skilled staff turnover, referral source attrition, and billing system migration errors. Staff turnover risk is mitigated by retaining the acquired agency's director of nursing and administrator under 12–24 month employment agreements with retention bonuses tied to census and quality metrics. Referral source attrition is mitigated by introducing the platform's regional clinical liaison to key referral sources within the first 30 days post-close and ensuring continuity of the personal relationships the prior owner had built. Billing system migration risk is mitigated by running parallel billing systems for 60–90 days post-migration and conducting a post-migration claims audit to identify any coding or submission errors introduced during the transition.
Yes, home health agencies are SBA-eligible businesses, and the SBA 7(a) program is commonly used to finance lower middle market acquisitions in this sector. A typical SBA-financed structure includes 75–80% SBA loan financing, 10–15% seller note (on full standby during the SBA loan term), and a 10% buyer equity injection. The primary SBA 7(a) consideration specific to home health is that the lender will require confirmation of Medicare certification status and a clean compliance history as part of underwriting, and the loan timeline must be coordinated carefully with the CHOW filing to avoid a scenario where the SBA loan closes but Medicare billing authority is delayed. Working with an SBA lender experienced in healthcare transactions significantly reduces execution risk.
CMS star ratings are critically important both to acquisition valuation and to the platform's exit multiple. At the acquisition stage, agencies with 4–5 star ratings command premium multiples because their clinical outcomes data validates the quality of care delivered and their PDGM reimbursement performance. At the platform exit stage, a portfolio of agencies with consistently improving or above-average star ratings demonstrates to strategic buyers and PE sponsors that the platform's clinical protocols are working and that the business is well-positioned under CMS's Home Health Value-Based Purchasing program. Platforms with average portfolio star ratings below 3.0 will face significant buyer scrutiny and potential purchase price discounts at exit, making clinical quality improvement a core value creation priority from the first acquisition forward.
The optimal payor mix for exit positioning is approximately 60–70% traditional Medicare, 15–20% Medicare Advantage, 10–15% Medicaid, and 5–10% private pay or commercial insurance. Pure Medicare fee-for-service dependency — agencies deriving 85–90% of revenue from traditional Medicare — creates reimbursement concentration risk that institutional buyers discount heavily, given the exposure to annual PDGM rate adjustments. Medicare Advantage and managed care contracts demonstrate the platform's ability to perform under value-based arrangements and provide revenue diversification that supports higher exit multiples. Building managed care contracting capability is typically a mid-to-late stage roll-up priority once the platform has sufficient geographic coverage and patient volume to be an attractive network partner for regional health plans.
More Home Health Agency Guides
More Roll-Up Strategy Guides
Build your platform from the best Home Health Agency operators on the market — free to start.
Create your free accountNo credit card required
For Buyers
For Sellers